Navigation Links
Stemedica Announces the Appointment of Dr. Lev Verkh as Chief Regulatory and Clinical Development Officer

Stemedica announced today the appointment of Lev Verkh, PhD as Chief Regulatory and Clinical Development Officer. Dr. Verkh will be responsible for managing all regulatory activities and clinical trials on behalf of the company.

(PRWEB) June 11, 2010 -- Stemedica Cell Technologies, Inc., a leader in adult stem cell research and manufacturing, announced today the appointment of Lev Verkh, PhD as Chief Regulatory and Clinical Development Officer. Dr. Verkh will be responsible for managing all regulatory activities and clinical trials on behalf of the company. "Dr. Verkh brings over twenty years of international regulatory and clinical trial experience to Stemedica," said Dr. Nikolai Tankovich, Stemedica's President & Chief Medical Officer. "We are confident that his contribution to our mission to bring innovative products to patients, following FDA guidelines, will be significant."

Dr. Verkh's clinical and regulatory experience includes working for Pfizer, Baxter Bio Sciences, the Alliance Pharmaceutical Corporation and the Alpha Therapeutic Corporation. He has directed national and multi-national Phase I, II, III and IV clinical trials in such areas as cardiology, oncology, peripheral artery disease, hematology, blood disorders and imaging methods. He is author or co-author of over 40 peer-reviewed publications. Through his efforts and the efforts of his teams, he has received FDA approval for several products that are currently on the market. "I am honored to be joining Stemedica's management team," said Dr. Verkh, "and am excited to work with the company's leading-edge stem cell technology."

In addition to directing Stemedica's clinical trials within the United States, Dr. Verkh will be assisting foreign regulatory agencies to establish guidelines for stem cell technologies in medicine. He will also assist in organizing and supervising clinical trials outside the United States utilizing Stemedica technology.

"With the rapid advancement of clinical application and development of adult stem cell technologies around the world, the addition of Dr. Verkh is essential to our long-term growth plan", said Maynard Howe, PhD, Stemedica's Chief Executive Officer. "Stemedica is working closely with government leaders, scientists and clinicians to establish and promote best scientific practices in the emerging field of stem cell research and therapy."

About Stemedica Cell Technologies, Inc.
Stemedica Cell Technologies Inc. ( is a specialty biopharmaceutical company that is committed to the development and manufacturing of best-in-class allogeneic adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and human stem cell clinical trials. The company is currently developing regulatory pathways for stroke and wound repair. Stemedica is headquartered in San Diego, California.

Media Contact for Stemedica: Dave McGuigan at dmcguigan (at) stemedica(dot)com

# # #

Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Stemedica Completes Meeting with the FDA
2. United States Patent and Trademark Office Publishes Stemedica's Patent Application for the Treatment of Diabetic Retinopathy
3. The Jordanian Stem Cell Company Acquires Stem Cell Technology From Stemedica International S.A. - First Clinical Trail Anticipated To Begin Early 2010
4. Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells
5. Stemedica Selected By World Stem Cell Summit To Present Scientific Discoveries
6. Stemedica Requests Pre-IND Meeting With FDA
7. Stemedica Signs Scientific Advisory Board Agreement with Leading Pediatric Burn & Wound Care Researcher
8. Renowned Stem Cell Researcher Files Study Results With Stemedica
9. CIRM Completes Briefing Visit to Stemedica Cell Technologies
10. Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services
11. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
Post Your Comments:
Related Image:
Stemedica Announces the Appointment of Dr. Lev Verkh as Chief Regulatory and Clinical Development Officer 
(Date:11/26/2015)... , England , November 26, 2015 /PRNewswire/ ... Medical, an innovative medical device company specializing in imaging technologies, ... from the European Commission as part of the Horizon 2020 ... company to carry out a large-scale clinical trial in breast ...      (Logo: , --> ...
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE ... has adopted a stockholder rights plan (Rights Plan) in ... operating loss carryforwards (NOLs) under Section 382 of the ... --> PharmAthene,s use of its NOLs could ... change" as defined in Section 382 of the Code. ...
(Date:11/25/2015)... -- Studies reveal the differences in species ... the way for more effective treatment for one of the ... --> --> Gum disease ... cats, yet relatively little was understood about the bacteria associated ... conducted by researchers from the WALTHAM Centre for Pet Nutrition ...
(Date:11/25/2015)... DIEGO , Nov. 25, 2015  Neurocrine Biosciences, ... Kevin Gorman , President and CEO of Neurocrine Biosciences, ... Healthcare Conference in New York . ... to visit the website approximately 5 minutes prior to ... A replay of the presentation will be available on ...
Breaking Biology Technology:
(Date:11/18/2015)... , November 18, 2015 ... has published a new market report titled  Gesture Recognition ... and Forecast, 2015 - 2021. According to the report, the global ... and is anticipated to reach US$29.1 bn by 2021, ... North America dominated the ...
(Date:11/16/2015)... Nov 16, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced expansion of its TDDI product ... touch controller and display driver integration (TDDI) solutions ... These new TDDI products add to the previously-announced ... TD4302 (WQHD resolution), and TD4322 (FHD resolution) solutions. ...
(Date:11/10/2015)... LONDON , Nov. 10, 2015 /PRNewswire/ ... segmented on the basis of product, type, ... segments included in this report are consumables, ... this report are safety biomarkers, efficacy biomarkers, ... in this report are diagnostics development, drug ...
Breaking Biology News(10 mins):